Key result
No clinical data is available as the provided text is a copyright transfer and author contribution form.
This review summarizes the mechanism, incidence, assessment, and treatment of paravalvular aortic regurgitation, a prominent limitation following transcatheter aortic valve replacement.
Answers are grounded in this paper and cite their sources.
No clinical data extractable from this form; leaves open the evidence base for paravalvular AR management after TAVR.
Transcatheter aortic valve replacement (TAVR) is a rapidly evolving technology that has been accepted as a treatment option in patients with severe aortic stenosis who are not suitable for or are at high risk for conventional surgery. Randomized trials have shown that TAVR decreases mortality and improves quality of life in patients who are not suitable for conventional surgery and that TAVR is not inferior to standard surgery in operable but high- risk patients. However, TAVR has several important limitations, the most prominent of which is residual paravalvular aortic regurgitation (PAR). The purpose of this review is to present the mechanism, incidence, assessment, and treatment of PAR after TAVR.
No takes yet. Share an insight, caveat, or question.
Barış Buğan (2014) studied Paravalvular aortic regurgitation after transcatheter aortic valve replacement. Transcatheter aortic valve replacement was evaluated. No clinical data is available as the provided text is a copyright transfer and author contribution form.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: